Updated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform?
about
Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA).Colistin Dosage without Loading Dose Is Efficacious when Treating Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia Caused by Strains with High Susceptibility to Colistin.Defining the incidence and risk factors of colistin-induced acute kidney injury by KDIGO criteriaSubstantial Targeting Advantage Achieved by Pulmonary Administration of Colistin Methanesulfonate in a Large-Animal Model.Untargeted metabolomics analysis reveals key pathways responsible for the synergistic killing of colistin and doripenem combination against Acinetobacter baumannii.Multidrug-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin-resistant enterococci: Three major threats to hematopoietic stem cell transplant recipients.Colistin: still a lifesaver for the 21st century?Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae.Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B?Dosing guidance for intravenous colistin in critically-ill patients.Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity.Clinical Pharmacokinetics and Pharmacodynamics of Colistin.Polymyxin Resistance in Gram-negative Pathogens.Pharmacokinetic/toxicodynamic analysis of colistin-associated acute kidney injury in critically ill patients.Efficacy of nebulized colistin-based therapy without concurrent intravenous colistin for ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii.Nebulized antibiotics in mechanically ventilated patients: roadmap and challenges.Nephrotoxicity in Patients with or without Cystic Fibrosis Treated with Polymyxin B Compared to Colistin.Colistin AUC in children treated with intravenous loading dose and maintenance therapy.Reply to Corona and Cattaneo.Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis.Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models.Pharmacokinetic/pharmacodynamic parameters for treatment optimization of infection due to antibiotic resistant bacteria: a summary for practical purposes in children and adults."Salvage treatment" for infections by extensively- and pan-drug-resistant pathogens is common and often sub-optimal.Editorial Commentary: Colistin and a New Paradigm in Drug Development.The Antihistamine Drugs Carbinoxamine Maleate and Chlorpheniramine Maleate Exhibit Potent Antiviral Activity Against a Broad Spectrum of Influenza Viruses
P2860
Q26739860-502DD1C2-3347-4FDC-91AB-D6E1AB757361Q36228369-89E92B39-2321-45EA-A1E7-C5E31CD421BDQ36299428-5B93B64D-D804-4699-BBD4-C7FC4A204A13Q37538748-3F5999BF-0CCE-4368-9D6D-CB95E21DB366Q37728145-2920FE05-2BFE-42E0-91B8-92C52EE9C330Q38620812-6CF2D62C-4B5F-4F09-812A-2C7121B8E43FQ38940249-049DD58B-671F-4F27-929C-1B5C55D9E6E1Q38944862-50E6E215-2D47-4B00-B6C5-098F3C12482FQ38994000-58825A7A-7F0C-4C03-A3D6-79A3BE6F7AAEQ39043757-68C02014-4224-447F-8A17-C06891023C5FQ39067724-CF62BE7E-5645-47C5-A6B8-960ACE15ECA7Q39170954-E612A635-75DC-4F73-8FCC-8C0EB64BA8FBQ39333751-D1E0CD5B-0737-419B-BF76-B43FDD7A8C5BQ40051834-29D29619-74A7-4DBF-BFD8-7B95F7730B8DQ40052709-C08D40FE-3AEA-4F66-A688-5CF8EAF91D3CQ40234980-A0901975-4280-4A61-B733-25D3050EABFBQ40422166-D82F600F-0DDC-4714-B41B-7CDF0BFF35E7Q41695302-B67DC11A-E4BF-4AC4-9012-BC3C645CD1D6Q41987068-5C8DD5BB-E631-4C4E-B91A-EAA448B5F594Q41987690-54891C90-5FF2-4E9A-BE02-11EDCC32E780Q47143645-260D57FC-5A0A-49F4-966E-C2C48FDFE571Q47391725-5C40151D-2CD4-4F24-83C7-C875739F33EFQ48197188-C6108606-6CF5-4D6E-A34B-68B50D54E6A0Q48275485-0CC9A789-4073-48FE-A132-4E327EB6226BQ53807986-24A47622-0D62-42F2-B621-2C6EF9ACACB3Q59136444-84BA4D1F-E337-4021-9A12-467C9BC6F4DD
P2860
Updated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform?
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Updated US and European Dose R ...... Colistin: How Do They Perform?
@ast
Updated US and European Dose R ...... Colistin: How Do They Perform?
@en
type
label
Updated US and European Dose R ...... Colistin: How Do They Perform?
@ast
Updated US and European Dose R ...... Colistin: How Do They Perform?
@en
prefLabel
Updated US and European Dose R ...... Colistin: How Do They Perform?
@ast
Updated US and European Dose R ...... Colistin: How Do They Perform?
@en
P2093
P2860
P50
P356
P1476
Updated US and European Dose R ...... Colistin: How Do They Perform?
@en
P2093
Alan Forrest
Evangelos J Giamarellos-Bourboulis
Fernanda P Silveira
John D Turnidge
Samira M Garonzik
Visanu Thamlikitkul
P2860
P304
P356
10.1093/CID/CIV964
P407
P577
2015-11-25T00:00:00Z